These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9381027)

  • 1. [Advantages in long-term treatment with Cognex in Alzheimer disease].
    Gracon S; Smith F; Shokry A
    Praxis (Bern 1994); 1997 Aug; 86(35):1350-4. PubMed ID: 9381027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Starting Alzheimer therapy in early stages whenever possible. Activities of daily living remain intact longer].
    Fuchsberger T; Padberg F; Faltraco F; Möller HJ; Hampel H
    MMW Fortschr Med; 2002 May; 144(20):36-9. PubMed ID: 12119881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictors of long-term institutionalization in patients with Alzheimer's disease: role of caregiver burden].
    Hirono N; Tsukamoto N; Inoue M; Moriwaki Y; Mori E
    No To Shinkei; 2002 Sep; 54(9):812-8. PubMed ID: 12428367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's disease.
    Wlodarczyk JH; Brodaty H; Hawthorne G
    Arch Gerontol Geriatr; 2004; 39(1):25-33. PubMed ID: 15158578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease: diagnosis, costs, and dimensions of treatment.
    DeKosky ST; Orgogozo JM
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S3-7. PubMed ID: 11669507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.
    Rockwood K; Black S; Bedard MA; Tran T; Lussier I;
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL.
    Jönsson L; Andreasen N; Kilander L; Soininen H; Waldemar G; Nygaard H; Winblad B; Jönhagen ME; Hallikainen M; Wimo A
    Alzheimer Dis Assoc Disord; 2006; 20(1):49-55. PubMed ID: 16493236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical treatment strategies for patients with Alzheimer's disease.
    Christensen DD; Lin P
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S17-23. PubMed ID: 18664338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term rivastigmine treatment in a routine clinical setting.
    Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
    Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Challenging pharmacotherapy in dementia].
    Ihl R
    MMW Fortschr Med; 2009 Mar; 151(13):46-8. PubMed ID: 19504818
    [No Abstract]   [Full Text] [Related]  

  • 16. [Early recognition not hopeless. Alzheimer disease can be delayed].
    MMW Fortschr Med; 2001 Feb; 143(6):60. PubMed ID: 11247376
    [No Abstract]   [Full Text] [Related]  

  • 17. [Patient-relevant end points in Alzheimer's disease].
    Frölich L
    Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S31-4. PubMed ID: 16688663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current antidementive therapy].
    Perneczky R; Kurz A
    MMW Fortschr Med; 2004 May; 146 Spec No 2():53-6. PubMed ID: 15376702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.
    Chibnall JT; Tait RC; Harman B; Luebbert RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1921-9. PubMed ID: 16274373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.